超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

加拿大Caprion Proteomics
Caprion Pharmaceuticals Inc. (蒙特利爾，Montreal)宣布和ICOS Corporation公司進(jìn)行一項(xiàng)新增的研究合作案。新的合作合約主要是采用Caprion公司的CellCarta(R) proteomics discovery platform蛋白質(zhì)體學(xué)研發(fā)科技平臺(tái)，應(yīng)用在生物指標(biāo)分子開(kāi)發(fā)方面。Caprion公司將配合ICOS Corporation公司在臨床前的癌癥研究計(jì)劃，去找尋血漿中可以作為藥物動(dòng)力學(xué)的分子。Caprion公司這項(xiàng)有專(zhuān)利的蛋白質(zhì)體學(xué)研發(fā)科技平臺(tái)，可以很有系統(tǒng)性的把在組織中或血漿中所找到的蛋白質(zhì)群進(jìn)行整理歸類(lèi)，以確定其基因表現(xiàn)和蛋白質(zhì)本身的特性。此外，Caprion公司目前正在以生物指標(biāo)開(kāi)發(fā)技術(shù)，也在其它一些醫(yī)學(xué)應(yīng)用方向，提供其它一些醫(yī)藥和生技公司項(xiàng)目研究方面的服務(wù)。


Caprion’s leading and proprietary proteomics discovery technologies - CellCarta? - enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly reduce risk and enhance clinical development productivity and decision making in pharmaceutical research.

--------------------------------------------------------------------------------

CellCarta? Discovery Platform
Caprion’s proteomics discovery platform - CellCarta? - is the leading means for profiling proteins in solid tissues and plasma. CellCarta? is a proprietary, state-of-the-art proteomics technology platform that serves as an engine for unparalleled disease target identification, predictive medicine and the creation of a proprietary therapeutic product pipeline. The power of Caprion’s technology has been successfully leveraged to secure multiple, platform-validating, revenue generating partnerships surrounding oncology therapeutic target identification and clinical biomarker discovery.